Phase 1 Study of Everolimus in Combination With Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 26 Dec 2018
Price : $35 *
At a glance
- Drugs Brentuximab vedotin (Primary) ; Everolimus (Primary)
- Indications Hodgkin's disease
- Focus Adverse reactions
- 17 Dec 2018 Status changed from suspended to active, no longer recruiting.
- 13 Nov 2018 Status changed from recruiting to suspended as per study design.
- 09 Apr 2018 Status changed from suspended to recruiting.